Provided by Tiger Trade Technology Pte. Ltd.

IO Biotech, Inc.

0.8685
+0.05857.22%
Volume:505.96K
Turnover:432.72K
Market Cap:62.49M
PE:-0.65
High:0.8800
Open:0.8046
Low:0.8010
Close:0.8100
52wk High:2.79
52wk Low:0.3234
Shares:71.95M
Float Shares:31.16M
Volume Ratio:0.58
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3356
EPS(LYR):-1.4494
ROE:-240.48%
ROA:-88.58%
PB:68.59
PE(LYR):-0.60

Loading ...

IO Biotech Q2 EPS $(0.40) Misses $(0.35) Estimate

Benzinga
·
Aug 15

IO Biotech Q2 Pretax Profit USD -26.099 Million

THOMSON REUTERS
·
Aug 15

IO Biotech Inc - Expects That Co Will Have Sufficient Cash to Run Company Into Q1 of 2026

THOMSON REUTERS
·
Aug 15

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

GlobeNewswire
·
Aug 15

IO Biotech Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
Aug 12

BUZZ-U.S. STOCKS ON THE MOVE-Elf Beauty, Intel, Archer Aviation

Reuters
·
Aug 12

BUZZ-IO Biotech drops after cancer vaccine narrowly misses main goal of late-stage study

Reuters
·
Aug 11

IO Biotech Shares up 12.2% at $2.03 Premarket in Volatile Trading Shortly After Trading Halt

THOMSON REUTERS
·
Aug 11

IO Biotech Shares up 56.9% Premarket After Co Reports Late-Stage Data for Therapeutic Cancer Vaccine

THOMSON REUTERS
·
Aug 11

IO Biotech Announces Promising Results in Phase 3 Trial of Cylembio Plus KEYTRUDA for Advanced Melanoma, Plans FDA Meeting

Reuters
·
Aug 11

IO Biotech Inc - Cylembio Plus Keytruda Well Tolerated With No New Safety Signals

THOMSON REUTERS
·
Aug 11

IO Biotech Inc - Plans FDA Meeting This Fall for Regulatory Submission

THOMSON REUTERS
·
Aug 11

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® Plus Keytruda® (Pembrolizumab) for the Treatment of First-Line Advanced Melanoma, but Statistical Significance Narrowly Missed

THOMSON REUTERS
·
Aug 11

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

GlobeNewswire
·
Aug 10

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 08

IO Biotech Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
Jul 30

BRIEF-IO Biotech Files Prospectus Relates To Resale, From Time To Time For Offering Of Up To 4.2 Million Shares By Selling Stockholders- SEC Filing

Reuters
·
Jul 25

IO Biotech Files Prospectus Relates to Resale, From Time to Time for Offering of up to 4.2 Mln Shares by Selling Stockholders- SEC Filing

THOMSON REUTERS
·
Jul 25

IO Biotech Inc. Issues Tranche B Warrant for 4.22 Million Shares at $1.3159 per Share in Connection with €12.5 Million Loan Drawdown

Reuters
·
Jun 28

IO Biotech Inc. Announces New Severance Compensation Terms for CEO in Event of Qualifying Termination

Reuters
·
Jun 21